Xenetic Biosciences Q3 Revenue Jumps 66.7%, Advances Oncology Program and Strengthens Financial Position

Xenetic Biosciences reported a 66.7% YoY increase in Q3 revenue to $1 mln, driven by its systemic DNase I program in oncology. A recent public offering has strengthened the company's financial position, supporting ongoing research and development efforts. Xenetic is advancing its XCART platform technology and PolyXen drug delivery platform, with a focus on high-value oncology indications. The company operates within the biotechnology industry with a market capitalization of $6.01 mln.